What question did this study set out to answer?

To evaluate the efficacy of liposomal irinotecan combined with fluorouracil and leucovorin in treating advanced biliary tract cancer after gemcitabine-cisplatin therapy.

March 3, 2026Open Access

OP2-2 Liposomal irinotecan with fluorouracil and leucovorin as salvage treatment for advanced biliary tract cancer refractory to gemcitabine and cisplatin

Key Points

To evaluate the efficacy of liposomal irinotecan combined with fluorouracil and leucovorin in treating advanced biliary tract cancer after gemcitabine-cisplatin therapy.
Patients with advanced biliary tract cancer were treated with liposomal irinotecan, fluorouracil, and leucovorin.
Outcomes were assessed based on treatment response and survival rates.
Data from previous trials and real-world conditions were analyzed.
Liposomal irinotecan showed variable efficacy among patients.
Some patients demonstrated a positive response to the treatment.
Overall, the treatment was explored as a potential salvage option after progression on standard therapies.

Abstract

Biliary tract cancers (BTCs) are aggressive malignancies often diagnosed at advanced stages, with limited therapeutic options after progression on gemcitabine-cisplatin (GP) therapy. While liposomal irinotecan with fluorouracil and leucovorin (Nal-IRI/FL) has shown efficacy in prior trials, outcomes have been inconsistent, and real-world data remain limited.

OP2-2 Liposomal irinotecan with fluorouracil and leucovorin as salvage treatment for advanced biliary tract cancer refractory to gemcitabine and cisplatin

Key Points

Abstract

Cite This Study